Disain ja modelleerimine HIV-1 pöördtranskriptaasi ja Malaaria ravimite väljatöötamise varajases faasis by Viira, Birgit
1
Tartu 2017
ISSN 1406-0299
ISBN 978-9949-77-515-6
DISSERTATIONES 
CHIMICAE 
UNIVERSITATIS 
TARTUENSIS
166
 
BIRG
IT V
IIR
A
 
D
esign and m
odelling in early drug developm
ent in targeting H
IV-1 reverse transcriptase and M
alaria
BIRGIT VIIRA
Design and modelling in early drug
development in targeting HIV-1
reverse transcriptase and Malaria
DISSERTATIONES CHIMICAE UNIVERSITATIS TARTUENSIS 
166 
  
DISSERTATIONES CHIMICAE UNIVERSITATIS TARTUENSIS 
166 
 
 
 
 
 
 
 
 
 
BIRGIT VIIRA 
 
 
Design and modelling in early drug 
development in targeting HIV-1  
reverse transcriptase and Malaria 
  
 Institute of Chemistry, Faculty of Science and Technology, University of Tartu, 
Estonia 
 
This Dissertation is accepted for the commencement of the Degree of Doctor of 
Philosophy in Molecular Engineering on June 15, 2017 by the Doctoral 
Committee of the Institute of Chemistry, University of Tartu. 
 
Supervisor: Dr. Uko Maran 
 Institute of Chemistry, University of Tartu 
 
Opponent:  Professor Tom Solmajer, Scientific Counsellor, Laboratory 
for Molecular Modeling, National Institute of Chemistry, 
Ljubljana and Faculty of Pharmacy, University of Ljubljana, 
Slovenia. 
 
Commencement:  August 29, 2017 at 12:00, Ravila 14a, room 1021 
 
This work has been partially supported by Graduate School of Functional 
materials and technologies receiving funding from the European Regional 
Development Fund in University of Tartu, Estonia 
 
 
 
 
 
 
 
 
ISSN 1406-0299 
ISBN 978-9949-77-515-6 (print)  
ISBN 978-9949-77-516-3 (pdf) 
 
 
Copyright: Birgit Viira, 2017 
 
University of Tartu Press 
www.tyk.ee 
 
European Union
European Regional 
Development Fund
Investing
in your future
5 
TABLE OF CONTENTS 
LIST OF ORIGINAL PUBLICATIONS .......................................................  6 
LIST OF ABBREVATIONS ..........................................................................  7 
INTRODUCTION ..........................................................................................  8 
1.  LITERATURE OVERVIEW ....................................................................  10 
1.1.  Human immunodeficiency virus .......................................................  10 
1.1.1. HIV infection cycle .................................................................  11 
1.1.2. HIV-1 reverse transcriptase ....................................................  11 
1.2.  Malaria ...............................................................................................  14 
1.2.1.  The life cycle of malaria .........................................................  14 
1.3.  Link between HIV-1 and malaria ......................................................  18 
1.4.  Data curation and systemization ........................................................  19 
1.5.  Hierarchical classification of scaffolds ..............................................  20 
1.6.  Quantitative or qualitative structure-activity relationships ................  22 
2.  RESEARCH RESULTS ............................................................................  26 
2.1.  Curating in-house and literature data .................................................  26 
2.1.1.  Consolidation of in-house and literature data for  
the design of Malaria inhibitors ..............................................  26 
2.1.2.  Curating and filtering database data for modelling  
HIV-1 RT structure space .......................................................  29 
2.2.  Discovery and modification of bioactive compounds .......................  30 
2.2.1.  Discovery, design and synthesis of s-triazines as  
HIV-1 RT inhibitors ................................................................  30 
2.2.2.  Classification models for antimalarial compounds and 
experimental validation of predictions ....................................  33 
2.3.  Hierarchical classification of HIV-1 NNRTIs and NRTIs ................  34 
2.4.  QSAR-s for HIV-1 NNTRIs and NRTIs ...........................................  36 
3.  CONCLUSION .........................................................................................  38 
4.  SUMMARY IN ESTONIAN ....................................................................  40 
REFRENCES .................................................................................................  42 
APPENDIX 1 .................................................................................................  54 
ACKNOWLEDGEMENTS ...........................................................................  56 
PUBLICATIONS ...........................................................................................  57 
CURRICULUM VITAE ................................................................................  160 
ELULOOKIRJELDUS ...................................................................................  162
 
  
6 
LIST OF ORIGINAL PUBLICATIONS 
The present thesis is based on four articles: 
 
I. Viira, B.; Selytina, A.; García-Sosa, A.T.; Karonen, M.; Sinkkonen, J.; 
Merits, A.; Maran, U. Design, discovery, modelling, synthesis, and bio-
logical evaluation of novel and small, low toxicity s-triazine derivatives as 
HIV-1 non-nucleoside reverse transcriptase inhibitors. Bioorg. Med. Chem. 
2016, 24(11), 2519–29. DOI: 10.1016/j.bmc.2016.04.018 
 
II. Viira, B.; García-Sosa, A.T.; Maran, U. Chemical Structure and Correlation 
Analysis of HIV-1 NNRT and NRT Inhibitors and Database-Curated, 
Published Inhibition Constants with Chemical Structure in Diverse Data-
sets. J. Mol. Graph. Model. 2017, In Press.  
DOI: 10.1016/j.mgm.2017.06.019.  
 
III. Viira, B.; Gendron, T.; Lanfranchi, D.D.; Cojean, S.; Horvath, D.; Marcou, G.; 
Varnek, A.; Maes, L.; Maran, U.; Loiseau P.M.; Davioud-Charvet, E. In 
Silico for Antimalarial Structure-Activity Knowledge and Discovery of 
Novel Antimalarial Curcuminoids. Molecules. 2016, 21(7), 853.  
DOI:10.3390/molecules21070853. 
 
IV. Sidorov, P; Viira, B.; Davioud-Charvet, E.; Maran, U.; Marcou, G.; 
Horvath, D.; Varnek, A. QSAR modeling and chemical space analysis of 
antimalarial compounds. J. Comp. Aided. Mol. 2017, 31(5), 441–451.  
DOI: 10.1007/s10822-017-0019-4 
 
 
Thesis author contribution to the articles: 
I. Performed synthesis of s-triazines and took part in discovery of novel, small 
and low toxicity s-triazine derivatives. Performed HPLC-MS and NMR 
(nuclear magnetic resonance) analysis and wrote the synthesis part and 
contributed to the analysis/discovery part of the manuscript. 
II. Designed and curated focused HIV-1 RT chemically diverse data set and 
analyzed this data using hierarchical classification of scaffolds and derived 
QSAR models for the HIV-1 NNRTIs and NRTIs subsets. I wrote most of 
the manuscript (data curation and respective data analysis). 
III. Designed focused database and curated data for antimalarial compounds 
from in-house and public data sources. Participated in model building 
process and wrote the database design portion of the manuscript. 
IV. Designed focused database for antimalarial compounds from in-house and 
public data sources and participated in writing the manuscript. 
  
7 
LIST OF ABBREVATIONS 
2,6-DATHTP 2,6-diaryltetrahydrothiopyran-4-ones 
AIDS Acquired Immuno Deficiency Syndrome  
DAA diaryllideneacetone  
DNA deoxyribonucleic acid 
EC50 half-maximal effective concentration 
ED50 half-maxima effective dose  
eq  equivalent 
FDA Food and Drug Administration  
HIV  human immunodeficiency virus 
HIV-1, HIV-2 human immunodeficiency virus type-1, type-2 
HPLC High-Performance Liquid Chromatography 
IC  information content 
IC50  half-maximal inhibitory concentration 
ISIDA In Silico design and Data Analysis 
Ki  equilibrium dissociation constant determined from an inhi-
bition assay 
LIBSVM Library for Support Vector Machines 
NNRTI non-nucleoside reverse transcriptase inhibitor 
NRTI nucleoside (nucleotide)-analogue reverse transcriptase inhi-
bitor 
R2  squared coefficient of correlation 
Ref  reference 
RNA ribonucleic acid 
RT  Reverse Transcriptase, reverse transcription 
rt  room temperature 
s2  squared standard error of regression 
SVM Support Vector Machine 
 
  
8 
INTRODUCTION 
The process of developing a new drug from scratch is time consuming and 
costly, taking approximately 10–15 years, and costs around 1 billion USD [1]. 
This process has been conventionally divided into five stages: (a) basic research, 
(b) lead target and lead compound(s) discovery, (c) preclinical development, (d) 
clinical development and (e) filing to drug administration agency. On this 
pipeline, the basic research stage (a) includes collection and investigation of 
available data and information about different targets, pathways, known drugs/ 
bioactive compounds and respective measured bioactivities to find a potential 
target and new compound(s) to work forward with. The lead target(s) selection 
of lead discovery stage (b) is a crucial step for helping to identify the most 
promising approaches before starting to look more into potential drug candi-
dates. The search of the lead compound(s) follows the successful selection of 
lead target(s) (b). The potential lead compounds have five general requirements 
[2]. At first, compound must be able to absorb into the bloodstream. For second, 
it must be able to locate and selectively bind to the proper site of the body. 
Thirdly, a compound must metabolize efficiently and effectively. Fourth, it 
must be easily extracted from the body after eliciting the desired functional 
response from the target. Last and most importantly, the compound must be 
non-toxic in in vitro and in vivo tests. In the preclinical development (c), the 
third stage in drug development pipeline, the goal is to make sure that the found 
lead compound(s) is (are) ready for clinical development. The clinical develop-
ment (d) mostly deals with the safety and efficacy issues on patients and 
includes: safety testing in small group of healthy volunteers (Phase I), safety 
and efficiency assessing in a small group of patients (Phase II), and safety and 
efficacy demonstration in a large group of patients (Phase III). After finishing 
all previously mentioned stages (a-d) successfully, the manufacturing part (e) of 
the new medicine follows. In developing a new drug, the basic research (a) and 
lead discovery stages (b) are the challenging steps and form the ground for the 
success in a drug discovery pipeline. This sets the focus of the present thesis on 
these first two stages (a, b), i.e. how to collect, curate and prepare data for the 
computational study, and how to discover and modify lead compound(s). 
The essential starting point in early drug development is the collection of 
existing knowledge about small molecule compounds, with indispensable steps 
of data curation and verification. Exponential growth of data entries and increase 
of data heterogeneity and complexity is making data assembly from different 
sources and diverse experimental protocols a more and more complex problem. 
The current thesis focuses on two highly prevalent infections affecting many 
regions in the world: malaria and human immunodeficiency virus 1. While 
working with anti-HIV-1 (human immunodeficiency virus type-1) compounds, 
the focus was two-fold. First, design, discovery, modelling, synthesis and bio-
logical evaluation of novel s-triazine derivatives (article I) and second, on 
chemical structure analysis of HIV-1 RT (reverse transcriptase, reverse 
9 
transcription) inhibitors with available equilibrium binding affinity data; 
revealing the structures of their scaffold trees and allowing to build QSAR 
models on this structurally diverse data (article II). When working with 
antimalarial compounds, the focus was at first on the data curation and focused 
database assembly (article III, IV) that allowed designing predictive models, 
which in turn allowed to suggest new chemical structures of the antimalarial 
curcuminoids, which were successfully externally validated (article III). In 
following chapters, general overview about HIV-1 and Malaria together with 
currently known drugs is given, followed by the overview of methods used in 
the current thesis. Then the research described in the articles will be 
summarized, along with the major conclusions.  
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1. LITERATURE OVERVIEW  
1.1. Human immunodeficiency virus 
The HIV (human immunodeficiency virus) targets the immune system and virus 
infection progresses to an advanced stage that causes AIDS (Acquired Immuno 
Deficiency Syndrome). The first case of AIDS was reported in USA in 1981 
within young homosexual men, who succumbed and eventually died due to the 
weakened immune system [3,4,5,6]. The HIV can be transmitted in multiple ways: 
unprotected sexual intercourse with an infected person, transfusion of 
contaminated blood and sharing of contaminated needles, syringes or other 
sharp instruments, and between a mother and her infant during pregnancy, 
childbirth and breastfeeding. It has been estimated by the WHO (World Health 
Organization) and UNAIDS (Joint United Nations Program on HIV and AIDS) 
that 36.7 million people are living with HIV around the world, particularly in 
Africa, being the epicenter of the epidemic [7]. Successful discovery of the HIV 
was made in two laboratories, by Robert Gallo and co-workers in USA [8,9] 
and by Luc Montaigner’s group in France [10]. In 2008, Luc Montagnier and 
Françoise Barré-Sinoussi received the Nobel Prize for their discovery of HIV. 
There are two different types of HIV: HIV-1 and HIV-2 (human immuno-
deficiency virus type-2). The HIV-2 has found to have the lower viral loads 
compared to the HIV-1 in infected individuals and lower transmission rates 
[11]. This could be the reason why the HIV-2 is not a pandemic virus like the 
HIV-1. Up to now, there is no vaccine for HIV-1 and the treatment should rely 
on suppressing its infection cycle with antiviral compounds. Till today, 28 
different such compounds have been licensed as anti-HIV drugs [12]. The FDA 
(Food and Drug Administration) has approved 24 drugs for treatment of HIV-1 
infections, that are divided into six distinct classes based on their molecular 
mechanism and resistance profiles [12]: (i) NRTIs (nucleoside(nucleotide)-
analogue reverse transcriptase inhibitors), (ii) NNRTIs (non-nucleoside reverse 
transcriptase inhibitors), (iii) integrase inhibitors, (iv) protease inhibitors, 
(v) fusion inhibitors and (vi) co-receptor antagonists. In medical treatment, the 
monotherapy was used in early 1990s, nowadays, more common is the dual 
therapy and the triple drug combinational therapy HAART (Highly Active Anti-
retriviral Therapy). [13,14,15] The latter was seminal in reducing the morbidity 
and mortality related with HIV-1 infection by suppressing dramatically viral 
load and resulting in a significant reconstitution of the immune system 
[16,17,18]. 
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1.1.1. HIV infection cycle 
The HIV strikes aggressively the immune system by attacking and killing CD4 
(cluster of differentiation 4) cells, which play an important role in fighting 
infections in body. The HIV life cycle has seven stages (Figure 1). At the first 
stage, the HIV binds to the CD4 receptors and co-receptors. Followed by the 
second fusion stage, where the HIV envelope joins the host CD4 cell membrane. 
In the third stage, reverse transcription of HIV RNA (ribonucleic acid) to DNA 
(deoxyribonucleic acid) takes place. Integration is the fourth stage, where the 
HIV releases integrase, using it to integrate HIVs viral DNA into the DNA of 
the CD4 cell. Integration is followed by replication (fifth stage), where HIV 
begins to make long chains of HIV proteins. To create a new infectious virion, 
new HIV proteins and HIV RNA assembles into non-infections HIV as sixth 
stage. Budding is the seventh stage, where newly formed non-infectious HIV 
buds itself out of the host CD4 cell and follows protease-mediated maturation to 
create an infectious viral particle. [19,20]. All mentioned stages are potential 
targets for antiretroviral drug discovery.  
 
 
1.1.2. HIV-1 reverse transcriptase 
Reverse transcriptase enzyme (revertase, RNA-dependent DNA polymerase, 
RdDp – RNA-dependent DNA polymerization) is responsible for synthesis of 
 
Figure 1. Schematic representation of the HIV life cycle. 1 – Binding; 2 – Fusion,  
3 – Reverse transcription, 4 – Integration, 5 – Replication, 6 – Assembly, 7 – Budding 
(explanation in the text). Figure adapted from https://aidsinfo.nih.gov/education-
materials/fact-sheets/19/73/the-hiv-life-cycle. 
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double-stranded DNA from the single-stranded viral RNA genome. Therefore, 
reverse transcription is a key step in the life cycle of retroviruses. Within 
current thesis, it is also a target used in studies. The HIV-1 reverse transcriptase 
enzyme is heterodimer, consisting two subunits: p51 (440 amino acids) and p66 
(560 amino acids). This enzyme exhibits two different enzymatic activities: a 
DNA polymerase activity, using RNA or DNA as a template and an endo-
nucleolytic RNase H (ribonuclease H) activity, destroying RNA in RNA:DNA 
heteroduplexes [21]. Currently, there are 13 HIV-1 RT antiretroviral agents 
approved by the U.S. FDA, classified into two different therapeutic groups: 
NRTIs (nucleotide/nucleoside analogue RT inhibitors) and NNRTIs (non-
nucleoside analogue RT inhibitors). 
 
 
 
Figure 2. Structure of NRTIs approved by the FDA. 
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Nucleoside (nucleotide) – analogue reverse transcriptase inhibitors: The 
nucleoside-analogue reverse transcriptase inhibitors were the first developed 
and proved to suppress HIV-1 replication as antiretroviral agents. In the mid-
1960s, AZT (azidothymidine or zidovudine) was initially synthesized as a 
potential anticancer agent, but failed and was put aside at that time [22,23]. 
About twenty years later, AZT was found to block the reverse transcription step 
of HIV-1 life cycle and was the first antiretroviral drug approved by FDA for 
clinical use [22,24,25]. Currently, there are eight available and approved NRTIs 
(see Figure 2) [26]. The NRTIs are nucleoside analogues (dNTPs – naturally 
occurring deoxyribonucleosides) and targeted to terminate the DNA chain 
synthesis, due to their lack of 3’-OH group on their sugar moiety [27]. The 
NRTIs act as prodrugs because they need to be converted to their active 
metabolites by cellular enzymes to compete with normal nucleotides for binding 
to the catalytic site of the RT [28]. The NRTIs are also known to be rather toxic 
due to the additional ability to inhibit the cellular DNA polymerases [29]. 
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Non-nucleoside reverse transcriptase inhibitors: Nevirapine is the first-
generation NNRTIs discovered in early 1990s. Currently, there are four available 
and approved NNRTIs (see Figure 3). [26] The NNRTIs are relatively small 
(<600 Da) hydrophobic compounds with high variety of structures (Figure 3) 
[21]. They all share the same mode of action, by binding directly and non-
competitively to an allosteric pocket site of HIV-1 RT, resulting in confor-
mational changes in the enzyme and polymerization inhibition [30]. As opposed 
to the NRTIs, the NNRTIs do not inhibit other RT lentiviruses like HIV-2 and 
SIV (simian immunodeficiency virus), therefore, NNRTIs are more selective 
compared to NRTIs [31,32]. The NNRTI resistance mutations can emerge 
relatively quickly. Therefore, NNRTIs are mostly used in combination with 
NRTIs, using the advantage of non-overlapping mechanisms and mutation sites. 
[27]. 
 
  
Figure 3. Structure of NNRTIs approved by the FDA. 
 
In addition to the four approved NNRTI molecules (Figure 3), there are about 
30 different structural classes of compounds reported as potential NNRTIs [33]: 
for example HEPT (1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thumine) deri-
vatives [34], TSAO (2’,5’-bis-O-(tert-butyldimethylsilyl)-3’-spiro-5”-(amino-
1”,2”-oxathiole-2”,2”-dioxide)pyrimidine) derivatives [35, 36], benzothiazine 
dioxides [37], N1,N3-disubstituted uracils [38], substituted S-DABOs  
(2-alkylsulfanyl-6-benzyl-3,4-dihydropyrimidin-4(3H)-ones) [39], 2-adamantyl-
substituted thiazolidin-4-ones [40], lectins [41], indolobenzothiazepinenones 
[42] and many others [43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56].  
Despite the large number of already known compounds and compound 
families, new compounds are searched for. This thesis has focused on s-triazine 
(1,3,5-triazines) derivatives that have not been extensively analyzed as NNRTIs. 
The s-triazines have been studied and used other in areas. They have found 
application in wide range, for example in anticancer therapy [57], estrogen 
receptor mo-dulators [58], antibacterials [59, 60], antimicrobals [60, 61, 62, 63, 
14 
64, 65, 66] and tumor growth inhibitors [67]. Due to large interest, different 
methods, for example solid phase [16] and combinatorial [9] synthesis, have been 
developed to synthesize the 1,3,5-triazines with diverse substitution pattern. The 
cyanuric chloride is the most common and practical starting reagent for 
synthesis of substituted 1,3,5-triazines (Figure 4) [68]. The nucleophilic 
substitution of each chloride could be controlled by taking into consideration 
the decrease in reactivity with increasing number of substituents (Figure 4) [69, 
70, 71, 72].  
 
 
Figure 4. Stepwise nucleophilic substitution of 1,3,5-cyanyric chloride. 
 
 
1.2. Malaria 
Malaria is a tropical disease, caused by Plasmodium parasites and affects about 
3.2 billion people around the world. Possible symptoms are high fevers, 
headache, muscle pain, chills, vomiting and in case of cerebral malaria, neuro-
logical complications may occur (brain injury and coma). The rise of morbidity 
and mortality is caused by the late discovery and lack of appropriate treatment 
of malaria [73]. Altogether, there are five parasite species known to cause 
malaria: P. falciparum, P. vivax, P. ovale, P. malarie and P. knowlesi. The most 
prevalent and dangerous, P. falciparum, is responsible for the severe form of the 
disease. The infected female Anopheles mosquitoes spread the parasites to 
people through bites. The infants, children under five years of age, pregnant 
women, non-immune migrants, mobile populations, travelers and patients with 
HIV/AIDS are population groups at considerably higher risk of contracting 
malaria and developing severe disease. [7] Currently, most blood infections 
could be treated with existing antimalarial drugs, but resistance is causing 
serious obstacles. The vaccine for malaria it is still under trial, therefore, the 
main strategies are to use LLINs (long-lasting insecticidal bed nets), RDTs 
(rapid diagnostic tests) and ACT (artemisinin-based combination therapy) as 
first-line treatment in endemic regions [74,75]. 
 
 
1.2.1. The life cycle of malaria 
Malaria can be transmitted from infected Anopheles mosquitos to humans, and 
the other way around (Figure 5). The malaria life cycle begins when the infected 
Anopheles mosquito bites a human (1). As a result, hundreds of sporozoites 
enter the bloodstream and move to the liver within 30 minutes to infect liver 
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cells (2). In liver, the parasites start reproducing rapidly and develop into 
schizonts (3), which rupture and release thousands of individual merozoites into 
the bloodstream (4). Mereozoites invade erythrocytes and multiply further and 
restart a new blood cycle every 48 hours (5), infecting more red blood cells, 
leading to the clinical symptoms of the disease and potential death if not treated. 
After passing more than ten days, some merozoites develop into gametocytes (6). 
Another mosquito sucks blood from an infected human (7), they take up the 
gametocytes, and the cycle continues. The gametocytes are ingested into the 
mosquito’s stomach and mature into gametes (8). The male gamete and female 
gamete fuse together and produce a zygote (9). The zygotes elongate into 
ookinetes and burrow through the stomach wall. Then the ookinete develop into 
an oocyst (11). The oocysts grow and rupture, releasing sporozoites (12). The 
sporozoites migrate to salivary glands and are ready to be injected and renew 
the cycle. [76,77] 
 
 
Figure 5. Schematic representation of the life cycle of the Malaria (explanation in the text).  
m
osquito gut
blo
od
sa
liv
ary
 gla
nd
liver
12
11
10
 9
 8  7
6
5
4
3
21
liver cell
merozoites
erythrocytic cycle
gametocytes
gametes
zygote
ookinete
oocyst
sporozoites
sporozoites
Mosquito stages
Human blood stages
Human liver stages
16 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Available and approved antimalarial drugs. 
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Figure 6. Continues 
 
Available drugs for malaria. During the erythrocytic cycle (stage 5 in Figure 
5), the host hemoglobin is digested and it leads to the production of free heme 
as a toxic product [78]. The free heme is detoxified as side product into the 
malarial pigment called hemozoin by the parasite [79,80]. This cycle is an 
important target pathway for numerous antimalarial drugs, mostly for compounds 
belonging to the aminoquinoline series [81]. Quinine (Figure 6) was the first 
known drug to be efficient against malaria and targeted the erythrocyte stage of 
the parasite. This was also the starting point for drugs, such as chloroquine, 
quinacrine and primaquine [82]. There is also atovaquone, which is one of the 
most widely used naphtoquinone drugs [83]. Currently, the WHO recommends 
using ATC (artemisinin combinational therapy). The ATC is targeted in 
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preventing gametocytogenesis (stages 6 in Figure 5) [84]. Also, other mecha-
nisms exist and for example, curcumin, a natural product, has been suggested to 
kill malarial parasites via induced ROS (reactive oxygen species) [85,86] and in 
this way contribute to ACTs as a valuable compound [87]. In total, 36 
antimalarial drugs are approved and available (Figure 6). 
 
Known antimalarial curcuminoids and its analogues: Amongst the antimarial 
compounds, the current thesis focuses largely on curcuminoids (particularly 
DAAs – diaryllideneacetones) and 2,6-DATHTP (2,6-diaryltetrahydrothiopyran-
4-one) series (Figure 7). The DAAs were reported to display an effect on 
several biological activities [88, 89, 90, 91], from anti-inflammatory, anticancer, 
antioxidant to antiparasitic activities and also antimalarial activities [87, 92, 93, 
94, 95, 96]. Curcumin is the base of turmeric spice and the major component of 
extracts of Curcuma longa. Demethoxycurcumin, bisdemethoxycurcumin and 
monocarbonyl curcuminoids (curcuminoid DAA analogues, R=H, or R=OMe, 
Figure 7) can also be extracted from Curcuma longa. [97]. The second series of 
interest were 2,6-DATHTP derivatives, which are acting as prodrug of DAA 
and therefore have possibilities as antimalarial candidates. Both DAA and  
2,6-DATHTP series were synthesized by dr. Davioud-Charvet’s group [98, 99, 
100, 101, 102]. 
 
 
Figure 7. Structures of natural curcumin and diarylideneacetone (DAA) derivatives that 
have been identified in Curcuma extracts. 
 
 
1.3. Link between HIV-1 and malaria  
About 36.7 million people are living with HIV-1, and 214 million malaria cases 
have been estimated worldwide in 2015 [103]. Therefore, both infections are 
critical global health problems, particularly in developing countries. The 
interaction between HIV-1 and Malaria is bidirectional [104], meaning that one 
infection will influence other infection, making it worse or/and the treatment 
more complicated. Observations on HIV-1 infected pregnant women [105,106] 
and adults [107,108] show that people with HIV-1 infection are at more risk of 
having faster development of malaria symptoms and developing severe malaria, 
than people without HIV-1 infection. Due to the increase of cellular immuno-
suppression, the immune response to malaria degrades and thus hamper to 
preventing malaria infection and suppression of parasitaemia [108]. The impact 
of malaria on HIV-1 is not so clearly distinguished, because immune cells must 
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be activated, to measure increased HIV-1 viral load [109]. The viral load 
measurement is performed to detect the amount of HIV in organism and track 
the progress of the infection. Hoffmann et al. [110] and Kublin et al. [111] have 
shown that malaria affects HIV-1 by increasing HIV viral load and accelerates 
disease progression. 
 
 
1.4. Data curation and systemization 
We are living in the era of chemical data expansion. The vast amount of 
chemistry data is available from databases that are today mostly online. Just to 
name a few that have open access: the NIST (National Institute of Standards 
and Technology) [112], the NCI (National Cancer Institute) [113], the NLM 
(National Library of Medicine) [114], ChemBank [115], PubChem [116], 
ChemSpider [117], ChEMBL [118], and DrugBank [119]. Private companies 
have also created many such databases: including CambridgeSoft [120], SRC 
(Syracuse Research Corporation) [121], SciFinder [122], etc. Many of these 
databases are also well annotated, i.e. different bits of data are connected to 
form information, making the data increasingly useful to aid in the early stages 
of drug discovery and design, through the application of different computational 
methods [123].  
Due to the vast amount of data available, crucial is the data systemization 
and curation relative to the research task. Therefore, creating a specialized and 
focused database or data set gathered from various (or even single) public and 
private data sources has become increasingly important task in early stage of 
drug discovery. Moreover, in large amounts of available data, some random 
errors produced by human entry and/or systematic errors generated by incorrect 
translation are inevitable, and therefore, the data curation process is an essential 
step in data pretreatment [124, 125]. Therefore, data curation and systemati-
zation has become an emerging issue and research area. It has been extensively 
discussed and solutions have been provided by several authors [126, 127, 128]. 
The correct data and the data curation are important in any research area and for 
computational modelers as well, because the correct data has a substantial 
impact on model outcome [124].  
While systematizing data and generating databases and data sets fit for 
purpose, it is utmost important that the obtained information about chemical 
structure and linked experimental data is accurate. Even small errors and non-
compatibility in data could lead into propagated and further significant errors. 
Therefore, reliability of chemical structure and data quality must be assessed. In 
the literature, one can find proposed workflows for data curation [126, 127, 128]. 
Analyzing these works one can see that they are composed of two bigger 
blocks: systematizing-curating data, and filtering data to make it fit for the 
modelling task. The main components of data systematizing-curation are 
assessing the reliability of data quality by identifying, characterizing compounds 
of interest and their experimentally data, using the original source and 
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information available. This follows a filtering process, where inorganics, organo-
metallics, counter ions and mixtures are removed, remained structures are 
normalized and then duplicates removed, etc., making the data set fit for the 
modelling. Finally, and ideally, the obtained data should be double-checked 
manually, if size of the dataset allows. In this thesis, the data curation is 
extensively used to build data sets and databases for both HIV-1 and malaria 
computational studies. Much of the emphasis in this work has been in 
comparing experimental protocols, in order to understand what type experi-
mental data can be used together, i.e. what data is compatible with each other. 
In addition to in-house data, the ChEMBL database as single source of external 
public data has been used in course of research in three articles (II, III, IV) of 
present thesis. 
 
 
1.5. Hierarchical classification of scaffolds 
The increasing amount of compound collections with biochemical information 
relevant to drug discover, has opened a need for methods for analyzing and 
systemizing molecular structures in order to understand the structural diversity 
and accompanying structural hierarchy of datasets in a systematic manner. 
Classification of chemical structures and understanding relationships between 
chemicals allows understanding and reducing the complexity of large compound 
libraries, by grouping similar or related molecules. Properties of chemicals are 
mostly determined by different functional groups attached and molecules sharing 
same scaffold could often share a common synthetic pathway(s) [129]. There-
fore, taking advantage of the knowledge of what kind of effect on a property of 
interest different scaffolds hold and knowing the synthesis pathways, the 
structures could be modified in a way that the scaffold can be changed, but its 
desirable properties will be preserved. Several methods and related computer 
programs for analyzing and visualizing chemical libraries have been presented 
in the scientific literature. For example, heat-maps and tree-maps are used to 
present clustered chemical structure data in eXplorer [130]. Radial clustergrams 
use adjacency of nodes to present parent-child relationships by displaying 
properties in the chemical structure tree [131]. HierS is an approach developed 
for compound clustering and analyzing high-throughput screening results by 
grouping molecular frameworks hierarchically based on the ring systems in the 
scaffolds that are obtained when all linker bonds are removed [132]. Leadscope 
Inc. has developed an analysis tool for complex data that uses a manually built, 
hierarchically sorted dictionary of cyclic and acyclic fragments to analyze 
structural data sets [133]. In HiTSEE (High-Throughput Screening Exploration 
Environment), the software focus is on structural similarities in the 
neighborhood of selected compounds rather than scaffolds. This allows also 
detecting activity cliffs by spotting big changes in size within a given cluster 
[134]. CheS-Mapper allows dividing large datasets with small compounds into 
clusters by arranging them based on their 3D similarity [135]. The SOMs (self-
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organizing maps) are used to cluster compounds in ChemSpaceShuttle, imple-
menting a non-linear encoder network and non-linear partial least squares for 
projection of high-dimensional descriptor vectors into a three-dimensional space 
[136]. The search and filtering of SMARTs, flags (threshold schemas) and 
molecular descriptors are used in Screening Assistant 2 allowing to integrate 
external sparse data in a flexible way via integrating data mining queries and 
management, interactive visualization, analysis of scaffolds [137]. The 
SARANEA (structure activity relationship and selectivity analysis) visualizes 
network of molecular graphs. The main feature of this tool is the calculation and 
visualization (through color) of a ‘cliff index’, describing the shifts between 
neighbors and mainly focused on the exploration of a large set of compounds 
[138]. The four level hierarchical clustering of compound structure, molecular 
and topological framework and terminal rings and bonds in SARConnect 
provides an interface for visualization molecular relationships via connecting 
targets, activities, and compounds from the major internal and external sources 
[139]. The two-side clustering analysis on drugs and targets based on iso-
morphism, substructure and fingerprint similarity searches allows to visualize 
the 2D small molecule structures and is implemented in DrugViz [140].  
In the current thesis, a hierarchical classification method of chemical struc-
tures implemented in Scaffold Hunter [141] has been used. The unique “parent” 
scaffolds for each molecule are generated by pruning all terminal side chains by 
preserving double bonds directly attached to the core structure. The 13 pre-
defined rules, which reflect the following synthetic and medicinal rationales, 
were used to stepwise simplify scaffolds by removing a single ring form the 
larger “child” scaffolds to generate smaller ‘parent’ scaffolds (with the lowest 
number of acyclic link bonds). The pruning of the molecules (ring system) will 
start with removing smaller rings first, those with the least number of 
heteroatoms. If the number of heteroatoms is equal, the priority of heteroatoms 
to retain is N > O > S. Rings with ≥ 12 atoms should not be removed until there 
are still smaller rings present, because a macrocycle is considered to be the most 
characteristic ring system occurring in a molecule. Bridged rings, spiro rings 
and nonlinear ring fusion patterns should be retained with preference, keeping 
in mind that bridged ring systems are retained with preference over spiro ring 
systems. When molecules contain linker(s), then firstly, the rings will be 
removed where the linker is attached to a ring heteroatom at either end of the 
linker. From a fully aromatic ring system, the rings should not be removed in a 
way that the resulting system is not aromatic any more. In case of a mix of 
aromatic and nonaromatic ring systems, the nonaromatic rings should be 
retained with priority. Finally, according to the tiebreaking rule, the compound 
whose canonical SMILES (simplified molecular-input line-entry system) based 
on the Molinspiration SMILES canonizer [142] has the lower rank in 
alphabetical order (A has a higher rank than B, and so on), will be removed 
first. The procedure terminates when a single ‘parent’ ring is obtained. As a 
result, hierarchical arrangement of “child” and ‘parent” scaffolds’ yield branches, 
which are connected to each other and combined to form a tree with compounds 
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which are connected to each other and combined to form a tree with compounds 
families. Branches can be annotated with available biological affinity constants 
and analyzed to see structure and activity relationships in a more detailed way.  
All of the above mentioned computational methods and tools allow making 
drug discovery and development faster and more economical, and making 
promising scaffolds, and their hierarchy more apparent. For example, the 
hierarchical classification method described in more detail above has proven its 
utility. Wetzel et al. have shown that information rich datasets obtained from bio-
chemical or biological screening of large compound libraries can be efficiently 
analyzed and navigated using hierarchical classification of scaffolds [143]. This 
method can also be used for linking chemical and biological space to define 
suitable starting points that guide the synthesis of compound collections with 
biological relevance [144]. 
 
 
1.7. Quantitative or qualitative structure-activity 
relationships 
The purpose of a (Q)SAR (quantitative or quantitative structure-activity relation-
ship) is to find and study relationships between physical or chemical properties 
or biological activity and the chemical structure of compounds when the 
structure has been expressed in the form of molecular descriptors. When this 
relationship is established and mechanistically explained, the final outcome will 
be predictive model(s) that allow to (computationally) estimate the activity or 
property of existing and novel compound(s). The schematic workflow displayed 
in Figure 8 explains the key steps in a (Q)SAR development and validation or 
application. The figure has been vertically organized into two groups, data 
preparation and computational (automated) steps. Horizontal view presents 
model development and model validation or application workflow. The process 
starts with data preparation (known also as data pre-treatment) that typically 
includes data collection, systematization and curation (see Chapter 1.4), 
followed by the training and validation set formation. Evaluation of the data 
quality and design of the training sets are crucial steps in the model building 
(see Chapter 1.4). It is utmost important to make sure that provided experi-
mental values are measured by using well-standardized assays, particularly, if 
the collected data is from different research groups and literature sources 
making data curation in that respect important step in data preparation for 
modelling [126, 127, 145, 146].  
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The next step for both horizontal workflows is geometry optimization that, 
depending on the need, can be accomplished on multiple levels of theory 
depending on the information one needs for the calculation of molecular 
descriptors and can therefore range from molecular mechanics calculations to 
quantum mechanical calculations. The geometry optimization can be skipped 
when only two-dimensional structures are needed for calculation of molecular 
descriptors. 
The calculation of molecular descriptors is the next step of the workflow. 
Molecular descriptors encode numerical information about the chemical 
structure. They can be classified into five groups: constitutional, topological, 
geometrical, electrostatic/charge-related and quantum chemical descriptors 
depending of the information they capture and level of the theory they have 
been used to be developed [148, 149, 150]. Molecular descriptors can be 
calculated for the whole molecule what is one of the most common approaches 
in modelling of bulk properties of chemicals. The descriptors can be calculated 
also for atoms and pairs of atoms being useful for modelling specific sites in the 
molecules and mostly in congeneric data series. The structural composition of a 
chemical can also be coded in larger fractions of chemical structures, i.e. 
fragments that are useful in analyzing substitution pattern of molecules, but also 
very diverse data sets. 
Molecular descriptors form knowledge space about structural information 
about molecules in the data set. It is an essential task to find in this knowledge 
space an appropriate descriptor or set of them that correlate with the property or 
activity under interest. The link between the molecular structure and the 
corresponding property/activity is usually achieved by means of statistical 
methods in a model development process. This process is usually the combi-
nation of a descriptors selection algorithm and a mathematical representation of 
model, often working hand-in-hand. Descriptors from a large pool can be 
selected in multiple ways ranging from forward and backward selection to 
 Figure 8. Schematic presentation for successful development of valid the QSARs 
(adopted from [147]) 
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genetic algorithms. A typical statistical method for mathematical representation 
of QSAR is the MLR (multi-linear relationship) method that is easy to under-
stand and the most commonly used method to provide insight to chemical 
phenomena via analyzing relationships between experimental values and mole-
cular descriptors. However, there are also several supervised and unsupervised 
data processing machine learning algorithms, such as kNN (k-Nearest 
Neighbors), SVM (Support Vector Machines), RF (Random Forests), DT 
(Decision Trees), PCA (Principle Component Analysis), PLS (Partial Least 
Squares), etc. that allow exploring complex relationships between structure and 
activity [151, 152].  
Once the model is obtained, reliability and fitting ability of the predictive 
model should be verified. This is done using the internal validation of LOO 
(leave-one-out) and LMO (leave-many-out) cross-validation techniques [153] or 
using external validation with a prediction set as indicated by the second 
workflow (Figure 8). In case of LOO and LMO, the activities of the syste-
matically or randomly excluded compounds are predicted using the developed 
model and gained predicted results are compared with experimental values. 
While using external validation, the prediction results characterized with the 
R2ext (square-root of correlation coefficient for the external validation set) must 
be comparable with the model R2 (square-root of correlation coefficient) value 
and they should be preferably similar (close to each other), the developed model 
to be valid. If the R2ext value is considerably higher than R2 value, then the 
model has been poorly represented by the training set. A component of model 
validation are also model diagnostics techniques that are carried out for the 
training, validation and also external validation sets in order to understand the 
applicability domain of the derived model. Simple and applicable to all types of 
the models is to analyze the ranges of molecular descriptors used in the models 
and also ranges of property or activity under the study. For the regression type 
of models, according to the literature, the most commonly used and visually 
appealing is juxtaposition of leverages and standardized residuals on one plot, 
commonly known as Williams plot. The leverage for compound is calculated 
from the matrix of molecular descriptors included into the model [154]. The 
standardized residuals are calculated from the difference between experimental 
and predicted value, divided by the standard error of the regression (s) of the 
training set. 
For the modelling of HIV-1 data within the given thesis (Chapter 2.4), the 
above described workflow computational steps include quantum chemical 
calculations implemented in MOPAC (Molecular Orbital PACkage) 6.0 [155], 
using eigenvector following geometry optimization algorithm [156] with AM1 
(Austin Model 1) parametrization [157]. The molecular descriptors were 
calculated with the CODESSA (COmprehensive DEscriptors for Structural and 
Statistical Analysis) 2.20 package [159] and were extended with logPOW 
(logarithm of octanol-water partition coefficient) values provided by the 
PubChem database (XlogP3 algorithm). The BMLR (Best Multi-Linear 
Regression) method that combines the forward selection of descriptors and 
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multi-linear regression was used to find relationships between the activities and 
molecular descriptors [148, 158, 159]. The mathematical representation of the 
model is simple and allows easy interpretation of the relationship between 
studied endpoint and chemical structure. The method identifies the orthogonal 
pairs of descriptor and extends the best correlations with the addition of new 
descriptors in step forward manner. In other words, the two-parameter 
regression models are built with the orthogonal pairs and certain number of 
models with the highest R2 are selected. New descriptors are added to each 
previous selected model and the models with higher number of parameters are 
built. The best presentation of the activity within calculated descriptors is the 
model with the highest R2 value. [148] The final MLR model that is close to an 
optimal description of the dataset within given set of descriptors. It was assessed 
using several statistical parameters: R2 (the squared coefficient of correlation), 
R2cv (leave-one-out cross-validated squared coefficient of correlation), R2ext 
(squared coefficient of correlation of external validation), Y-scrambled (1000 
randomization steps) R2scr (squared coefficient of correlation), F (Fisher’s 
criterion), s2 (the squared standard error of the regression), etc. 
For the modelling of curated antimalarial data (Chapter 2.1.1), the 
computational steps of the above workflow skip the geometry optimization step 
as the descriptors are calculated from the 2D representation of the molecular 
structure. The chemical structures were described with the 39 different ISIDA 
(In Silico design and Data Analysis) (for in silico design and data analysis) 
fragment descriptor series [160]. ISIDA have been used to develop new 
methods and original software tools for structure-property modelling and 
computer-aided design of new compounds [161, 162, 163]. The 39 descriptor 
schemes in ISIDA, correspond to different fragmentation strategies, starting 
from atom type to force field type-based atom coloring, that have been 
previously showed to be applicable to model a variety of different biological 
properties [163]. The activity values (IC50, EC50, etc) in antimalarial dataset 
were heterogenic, which limited the possibility to use regression type models 
and directed to the classification models while seeking relationships between 
activity and molecular descriptors. The models were selected using the 
evolutionary optimizer tool [164], designed for the LIBSVM (library for support 
vector machine algorithm [165]. The evolutionary optimizer produced for each 
data set a family of SVM classification models by simulating the Darwinian 
competition of parameter configurations (so called “chromosomes”). The 
models are ranked by a “fitness” score, which is an expression of the mean 
balanced accuracy of classification achieved during the repeated, three-fold 
cross-validation. Three-fold cross-validation means that the training set has 
been selected randomly and will be used for the model development and then 
challenged to predict the remaining compounds, kept out during the training 
(calibration) phase. 
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2. RESEARCH RESULTS 
The research results are presented in the conventional order of drug discovery 
and design during the basic research (a) and small molecule compound(s) 
discovery (b) stages. Research has been grouped into three major parts as 
carried out by the author of the thesis: the collection, curation and preparation 
of data for the computational study; discovery and modification of bioactive 
compounds; understanding and analyzing known chemical space for new 
discoveries and new in silico predictive models to facilitate new discoveries. 
 
 
2.1. Curating in-house and literature data 
During the research the tasks for the analysis, systematization, curation and 
filtering of data were varied. In one task, existing in-house data was curated and 
particularly measurement protocols were systematically analyzed and grouped, 
providing next step to the data curation, mapping in-house data with the 
database data with aid to extend the structural diversity of data for modelling 
purposes (Article III, IV). In the second task, the data in the public database was 
curated for the additional grouping and filtered for the analysis of structural 
space and in silico model development (Article II). 
 
 
2.1.1. Consolidation of in-house and literature data  
for the design of Malaria inhibitors 
The database or dataset for in silico predictive modelling requires the training 
sets to be as large and as diverse as possible. However, the particular problem in 
antimalarial research is not the scarcity, but the heterogeneity of the data, and 
one part of it is diversity and variability of experimental protocols used for the 
measurements. This makes it meaningful to assess the feasibility of fusing 
various protocol-specific sets into larger training sets. For that, one needs to 
understand protocols well and this forms the core of current data curation task. 
A challenge consisted of curating and fusing the various data sources, the in-
house data and literature data from the malaria subset of ChEMBL. To cope 
with this challenge, the strategy was introduced that allowed compiling coherent 
training sets where compound structures are associated to the respective 
antimalarial activity measurements. 
 
In-house protocols and corresponding chemical structures: The in-house 
source of the antimalarial data against the human pathogen Plasmodium 
falciparum in cell culture was measured at EDC’s (Dr. Elisabeth Davioud-
Charvet) laboratory (Article III), being the perfect starting point as the analysis 
protocols are in this case well known. The data structure was analyzed, 
systematized into five different data tables and organized into a database using 
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Instant JChem [166]. In this database, each chemical structure was associated 
with one or several experimentally determined antimalarial activity values. The 
structure of the tables and connections between the tables are available in 
Figure 9 and explained in more detail in the Appendix. All Structures, 
Properties (one for in-house and one for ChEMBL data), Protocols and 
References organized into the database showed that antimalarial activity has 
been measured in-house with eleven protocols for 266 recently synthesized 
compounds. The filtration of duplicates and salts left 182 compounds fit for 
further data consolidation and modelling tasks.  
 
When organizing data from multiple measurements, the coincidence of experi-
mental protocols becomes vital, because the conditions of antimalarial protocols 
tend to vary. In order to distinguish protocols, six relevant parameters were 
compared: strain of Plasmodium falciparum (Target organism), Drug exposure 
 
 
Figure 9. Connections between data tables. 
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time, Parasitic stage, Assay principle, Hematocrit % and Parasitema %. Number 
of compounds measured for these protocols ranged from 4 to 69. This data was 
solid and originated form one laboratory. Parameters relevant for the protocol 
were set for the purpose of potential expansion with data that is available from 
the literature and allows wider structural coverage for planned consensus 
modelling. 
 
Comparable protocols and data from ChEMBL: The most challenging in 
exploiting the antimalarial literature data is how to interpret the various 
protocols used for testing. The ChEMBL electronic database [118] (version 20) 
was used to increase the structural diversity and number of compounds in data 
series corresponding to the protocols used in-house. The structures and 
corresponding experimental data was retrieved with two different data queries. 
The purpose of the first query was to search for compounds that have available 
activity values measured using similar protocol conditions in comparison with 
in-house protocols. Only compounds were considered that have been reported 
with IC50 values in the nano-molar range in order for them to be comparable 
with obtained in-house data. The sixty-two compound series with 2295 
compounds match the query in ChEMBL database and were added into the 
combined EDC-ChEMBL antimalarial database. This primary search query was 
based on EDC in-house protocols, focused on protocol parameters, and 
therefore narrowed the search significantly.  
The second search query was broader, to fully exploit the malaria initiative 
data from ChEMBL and was therefore focused purely on the target, Plasmodium 
falciparum (Target ID: CHEMBL364), and therefore, search results included also 
EC50, ED50 values, etc., in addition to IC50. This resulted in 249,658 compounds 
with 400,176 measured activity values. The retrieved compounds were divided 
into 2,900 different experimental assay-based series. From the second query, the 
majority of data series were rather small (<50 compounds) and where therefore 
discarded. Thirty series containing more than 50 compounds were carefully 
studied for their data quality, keeping only dose-response-based activity values, 
and series that were redundant or with too few active compounds were 
discarded. Seven series fulfilled these criteria and were used in further work 
(CHEMBL730080, CHEMBL896244, CHEMBL896245, CHEMBL1038869, 
CHEMBL1038870, CHEMBL730081 and CHEMBL73061, in Article III).  
After merging EDC in-house and ChEMBL data series into the database, the 
structures were studied, chemically unstable structures were rejected, and the 
remaining structures were standardized using a virtual screening workflow 
installed on a web server realized with the ChemAxon toolkit [167]. This work-
flow was designed to remove compounds with heavy metal(s), molecules with 
high molecular weight, salts, N-oxides with split formal charges, convert com-
pounds to their predicted most stable tautomeric form and 5- and 6-membered 
aromatic rings to the “basic” aromatic forms, etc. After standardization of 
structures, duplicates were identified and removed. This activity completes the 
first stage in performing curation, standardization and organization of data that 
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was previously present in-house and based on the protocol information was 
complemented with the literature data (Article III, see Figure 3:a and 
accompanying description). 
The analysis of protocols and structural content of data series suggests 
merging the experimental data series into training sets. For this, two different 
steps were performed (Article III, Figure 3: b, c). In the first step, the six key 
parameters of in-house and ChEMBL protocols were compared and data series 
were merged if the protocol conditions overlapped (Article III, Figure 3: b). 
Five protocols shared the same protocol conditions and therefore could be 
merged. In the second step (Article III, Figure 3: c), the experimental values of 
most commonly used reference compounds (artemisinin, atovaquone and 
chloroquine) were compared. If their values are nearly equal (within expected 
experimental error, 0.5 log units for pIC/pEC), the series were further merged 
and the data sets’ chemical diversity was extended. Comparing the experimental 
values of reference compounds in each protocol also showed if there were any 
protocol parameters, out of six key parameters, which might not have a 
significant effect on the measured values and therefore could not be considered 
further. The comparison of experimental values of reference compounds 
resulted in two main conclusions. Firstly, the difference in Parasitema % does 
not have a significant influence on the measured bioactivity values of reference 
compounds compared to other five key parameters. Secondly, if assays were 
different (SYBRGreen or 3H-hypoxanthine), and all remaining conditions are 
same (Target organism, Drug exposure time, Hematocrit %, Parasitic stage), 
then they can be merged. As result, the 20 series were merged into 10 training 
sets pairwise. 
The total number of all merged series with the same protocol conditions and 
unmerged series formed together 30 training sets. Each of them included more 
than 50 molecules and span a significant activity range (i.e., contain both active 
and inactive) (Article III, Figure 3d). For seventeen of these training sets, 
successful consensus SVM classification models were obtained discriminating 
compounds that have a significant probability to be active under the specific 
conditions of the antimalarial test associated with each set (see further details in 
Chapter 2.2.2).  
 
 
2.1.2. Curating and filtering database data  
for modelling HIV-1 RT structure space  
In order to understand the structural space of HIV-1 RT inhibitors and derive in 
silico predictive models for estimating their equilibrium binding affinity, the 
data for HIV-1 was extracted from the ChEMBL database (version 20) (Article 
II). The primary search focused on the target “human immunodeficiency virus 
type 1 reverse transcriptase”, yielding 3 282 different structures with 7 187 
records of measured bioactivities (IC50, ED50, Ki, % inhibition, etc.). Extensive 
spreadsheet analysis of retrieved records made clear that several compounds 
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lacked available measured values (371), i.e., the column for the numerical value 
was left empty; or the value relationship was not always exact (1 179), i.e., it 
was higher or lower than a given value, or not available at all. While assembling 
data set with various measured bioactivities, the outcome is rather diverse and 
values from different methods or assays are not comparable with each other. 
The comparison of experimental methods or assay details can be very tricky, 
because not all details of methods or assays are always available. The precise Ki 
(equilibrium dissociation constant determined from an inhibition assay) values 
(i.e., the measured value equals a given numerical value) in the nM units were 
chosen as Ki values measured with different methods or assays are comparable. 
After applying previously mentioned steps, 234 Ki values out of 5 637 data 
points with experimental values remained in the data set, showing that 
impression on quantity of data can be deceptive. From the 234 data points, only 
the ones with the highest confidence score by ChEMBL (9 – direct single 
protein target assigned) were used. When one compound had more than one 
value with the same confidence score, then the median of experimental values 
was used. Unfortunately, the clear distinction between NRTI’s and NNRTI’s is 
not present in the ChEMBL and this requires extra data curation steps from the 
original literature. Indeed, the structures in ChEMBL allow a first premonition. 
However, to assure, that all compounds were grouped correctly, all the original 
references were evaluated also for the correctness of experimental values. This 
data was supplemented with two recently discovered new s-triazine derivative 
NNRTI inhibitors (Article I: compounds 18a and 18b in the original 
publication). The final dataset included altogether 71 compounds, with 39 
NNRTIs (Article II, Table 1) and 32 NRTIs (Article II, Table 2). From these 
tables, it could be seen that, in the case of NRTIs, the majority of compounds 
have more than one measured value with the same confidence score and the 
situation was the opposite for the NNRTIs. From this, one can make general 
conclusion, that NRTIs have more repeated measurements with different 
methods or assays to gain Ki value, than NNRTIs. Hierarchical clustering of 
chemical structures of these subsets is discussed in Chapter 2.3 and descriptive 
and predictive QSAR-s in Chapter 2.4. 
 
 
2.2. Discovery and modification of bioactive compounds 
2.2.1. Discovery, design and synthesis of s-triazines  
as HIV-1 RT inhibitors 
Previously carried out in silico screening by our research group [168] proposed 
several new chemicals as inhibitors for HIV-1 RT. A collaboration to experi-
mentally validate these chemicals resulted in Article I. Biological tests of sixteen 
compounds revealed compound 8 (in Article I, Table 1) as a new potent HIV-1 
RT inhibitor. The compound 8 belongs to the symmetric s-triazines and has not 
been described previously in HIV-1 research in any publication or patent. It 
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contains a diaryltriazine core substituted by three aminoalkyl groups, with two 
N-p-tolyl groups and one N-methyltetrahydrofuran group. The purity of the 
commercial sample 8 (n.p.- non-purified) was verified by HPLC-MS (High-
Performance Liquid Chromatography-Mass Spectrometry). Three additional 
distinctive components (in Article I, Figure S2, compounds 17, 18, 19) were 
detected, which together represented approximately 11% of the mass of the 
sample. These components were purified to homogeneity with HPLC and 
collected. Compounds 17 and 18 were collected together as a mixture, because 
they were failed to separate well under the used conditions/equipment and the 
amount of these compounds were considerably small. To verify the anti-
retroviral activity of compound 8, all of the obtained components of the sample 
(purified compound 8(p), 19, and mixture 17/18) were tested for their 
cytotoxicity and antiviral activity. Testing revealed that the mixture of 17/18 
was found to be the most active (in Article I, Figure S3) and also lacked any 
cytotoxic effect, even at highest concentration (in Article I, Figure S4). These 
results allow to conclude that instead of 8, components 17 and/or 18 must 
represent a potent HIV-1 RT inhibitor with a good therapeutic index. This 
finding also provided the grounds to speculate that the components discovered 
in the sample could be side-products from synthesis or intermediates and have 
structures similar to that of compound 8. Experimental and analytical testing 
and verification of the original components 17/18 and 19 were complicated due 
to the low amount (approximately 0.2 mg) in the commercial sample. Discovery 
of these compounds initiated the need for in house synthesis of predicteds-
triazine inhibitors (Article I). Considering the symmetric nature of the 
compound 8 core and the molar masses from the mass spectra of the sample 
components 17/18 and 19, and the synthesis pathways, possible structures were 
suggested (in Article I, Table 3). The molar mass for component 18 was 
307.4 g/mol, but considering the possible substitutions, it could match two 
structures that differ in one substituent (18a: –NH3+ or 18b: –OH). This 
conclusion led to the use of high-resolution LC-ESI-QTOF-MS (liquid 
chromatography-electronspray ionization-quadrupole-time of flight-mass spectro-
metry) to separate the original mixture 17/18 and determine the structure for 18. 
The latter showed that compound 18 must have a structure that contains two 
amino-tolyl and one hydroxyl group, i.e., compound 18b. These proposed 
structures were not reported before and neither were they commercially 
available. Possible methods for the synthesis of substituted 1,3,5-triazines were 
adopted from the literature and modified (Chapter 1.1.2). The functionalization 
of the less expensive reagent cyanuric chloride was selected as a promising 
approach. It has been shown that nucleophilic substitution of each chloride is 
successfully controlled by taking advantage of the decrease in reactivity with 
increase of the number of substituents. The 2,4,6-substituted 1,3,5-triazines 
were obtained from cyanuric chloride by sequential substitution of the chloride 
atom using nitrogen and oxygen centered nucleophiles (Figure 10), using 
different solvents and substituents to achieve the desired products. The current 
synthesis scheme enabled to obtain compounds 8, 17, 18a, 18b and 19 (in 
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Article I, Table 3) in large quantities and with considerable yield. Mono- and di-
substituted derivatives of 8 were prepared by the reaction of cyanuric chloride 
with the corresponding aminoalkyl group in DCM (dichloromethane) using di-
isopropyl amine as a base at ambient temperature (Figure 10 methods i and ii). 
In order to obtain the monosubstituted compound, the reaction was carried out 
at 0 °C or below. To substitute the first chlorine with an amino group, the 
solution was kept at rt (room temperature), and the reaction finished rapidly 
(Figure 10 method iii). The substitution of the remaining chloride atom(s) 
required higher temperature and longer reaction time (Figure 10 methods iv-vi). 
The yields of the obtained compounds were between 60–99% (Article I). 
Toxicity and antiretroviral activity of the synthesized compounds were analysed. 
The obtained results were consistent with previously obtained experimental data 
for sample components (in Article I, Section 2.2) and effective binding to the 
active site and structural interactions that determine these interactions were also 
verified computationally (in Article I, Section 2.4).  
 
 
 
Figure 10. General synthetic pathways used for the synthesis of 2,4,6-trisubstituted-
1,3,5-triazines. i) cyanyric chloride, p-toluene (2 eq), diisopropylamine (2.85 eq), DCM, 
0 °C to rt; ii) cyanuric chloride, tetrahydrofurane-4-amine (2 eq), diisopropylamine 
(2.85 eq), DCM, 0 °C to rt; iii) cyanyric choride, NH4OH (1 eq), DCM, rt; iv) 2,4-
dichloro-1,3,5-triazine, tetrahydrofurane-4-amine (2.5 eq), 1,4-dioxane, reflux; v) 2-
chloro-1,3,5-triazine, p-toluene (1.5 eq), 1,4-dioxane, reflux; vi) 2-chloro-1,3,5-triazine, 
tetrahydrofurane-4-amine (1.5 eq), 1,4-dioxane, reflux; and vii) 2-chloro-1,3,5-triazine, 
H2O (0.5 eq), dest.H2O, TFA, reflux. 
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2.2.2. Classification models for antimalarial compounds and 
experimental validation of predictions 
The 30 training sets resulting from the data curation and mixing from the two 
resources (described in Chapter 2.1.1) were subjected for building qualitative 
predictive models (methods in Chapter 1.6). The original experimental quanti-
tative values were converted into binary classes of “inactive = 1” and “active 
= 2”. Separation in each training set was done by picking the best cut-off values 
on the log scale of 7.5–6.0 and separating active compounds from inactive. The 
goal was to obtain the threshold for the active compounds between 1/3 and 1/4 
of the entire set. The cutoffs ranging from the micro-molar scale were increased 
stepwise by1/2 log until the previously set goal was achieved.  
The series of 39 different ISIDA fragment descriptor sets were calculated for 
each training set to find out which descriptor strategy would be the most 
suitable for defining the antimalarial activity. The LIBSVM support vector 
machine algorithm together with the evolutionary optimizer tool was used on 
the 30 training sets, to select the actual descriptor space for modelling. The 
“fitness” score, that gives the expression of mean balanced accuracy of 
classification achieved during the repeated three-fold cross-validation, was used 
to evaluate the models. The obtained models are consensus models, because 
they included several independent predictive equations, each calibrated on 
random subsets of the training set and then used to predict the remaining 
compounds kept out during the training (calibration) phase. The sets, which had 
fitness scores 0.7 and higher, were considered as sufficient. The seventeen sets 
out of initial 30 achieved this criterion (in Article III, Table 3, and Table S3 for 
more detailed information about experimental protocol). Each consensus model 
returns a real value likelihood (percentage) of the candidate to qualify as active, 
i.e. a “vote” towards the category in which a predicted molecule is assigned. 
The likelihood of around 50% is inconclusive, because this means that, out of 
the individual distinct equations composing the consensus model, those 
predicting “active” and “inactive” are roughly equal. The closer the likelihood is 
to 100%, the higher the trust is in the hypothesis that compound will be active. 
The 17 models were applied in virtual screening of 72 in-house compounds: 
35 symmetrical and dissymmetrical diarylideneacetone derivatives (DAA, see 
Article III, Table S1 for results) and 37 2,6-diaryltetrahydrothiopyran-4-ones 
(2,6-DATHTP, see Article III, Table S2 for results). Compounds were con-
sidered active if at least one model gave the likelihood to be active >70% or 
more than one model predicted the likelihood to be active >50% (see Article III, 
Tables S1 and S2 for assignments). According to this approach, 40 compounds 
(26 DAAs and 14 2,6-DATHTPs) were predicted to be active and 32 com-
pounds non-active against the 3D7 P. falciparum strain. From these compounds, 
31 compounds with best predicted properties (12 DAA and 19 2,6-DATHTP) 
including 27 with in silico status “A – active”, and four “I – inactive”, were 
tested for both their antimalarial potencies against P. falciparum and 
cytotoxicity against human fibroblasts MRC-5 strain (in Article III, Table 1, 2). 
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Out of predicted active 27 compounds, 17 were confirmed by the experiment (in 
Article III, Table 1 and 2). The correct predictions were obtained when at least 
one of the 17 used consensus models “voted” the compounds to be active by a 
large majority of >70%. The alternative selection scheme, voted active by at 
least two models at a low majority >50% of compounds, was less successful. 
Positive is also the fact that compounds predicted as inactive were indeed found 
as inactive in the experiment, providing extra validation for the computational 
approach used. 
 
 
2.3. Hierarchical classification of HIV-1 NNRTIs and NRTIs  
The HIV-1 NRTI’s and NNRTI’s structures curated and filtered (Chapter 2.1.2, 
and Article II) were analyzed with the hierarchical classification method, using 
the scaffold tree algorithm [129] implemented in the software Scaffold Hunter 
[141] (Chapter 1.5). This research was initiated to understand the chemical 
landscape in two series of inhibitors and, most importantly, how our new 
discovered s-triazines (in Article I, compounds 18a and 18b) position on this 
landscape.  
For 39 NNRTIs, hierarchical classification showed that current set is very 
diverse with ten different structural ‘parent types’: oxazepanone, diazepnanone, 
piperazinone, pyrazine, oxazinanone, diazinanone, pyridine, pyrrole, thiazole 
and triazine (in Article II, Table 1 and Figure 1). These NNRTI ‘parent types’ 
include at least one nitrogen atom and cycles vary from 5–7 atoms. Annotated 
activity constants for 39 compounds are from μM up to nM range. For detailed 
analysis of each branch, see Article II. As general conclusions, the identified 
scaffold branches and corresponding structures could be divided into four 
structural groups: PBO (pyrrolobenzoaxepine) derivatives [169] (oxazepanone 
branch); QXPTs (quinoxalinylethylpyridylthioureas) [170] (diazepanone, 
piperazinone, pyrazine, oxazinanone and diazinanone branch); halopyridyl and 
thiazolyl thiourea derivatives (pyrimidine and thiazole branch) and AAP-
BHAPs ((alkylamino)piperidine bis(heteroaryl)piperazine analogues) [171] 
(pyrrole branch). Two new compounds, 38 and 39 (in Article I compounds 18a 
and 18b respectively) form a separate branch and have a distinct difference 
compared with other curated NNRTIs, meaning that they a new family of 
symmetric NNRT inhibitors has been identified by the research carried out in 
the Article I. Their structural parameters common for typical lead compounds 
(molar weight of close to 300, etc.) allow to conclude that they could be further 
modified by adding beneficial substituents. When comparing their structure to 
those of the most active compounds, then an additional cycle with longer linker 
(ethylthiourea) could easily be added as a fourth cycle, which may increase their 
potency. Also possible is to modify their parent type by reducing the nitrogen 
atoms from three to two (pyrazine) or increasing the cycle by adding an 
additional carbon or even oxygen (oxazepanone) to make a ring with 7 or 8 
atoms. 
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The NRTI subset is less diverse in comparison with the NNRTI subset and 
includes four different ‘parent types’ (in Article I, Table 2 and Figure 14): 
uracil, pyrimidine, pyrimidione and imidazole. Named ‘parent types’ involve at 
least two nitrogen atoms and measured activity constants range from μM to nM. 
The detailed analysis of each branch is provided in the Article II. The example 
on Figure 11 depicts pyrimidine branch, providing color scheme of eliminated 
groups: at first eliminating functional groups (in red), then first ring (in blue), 
then second ring (in green), until the parent type structure remains (in black). 
The distribution of compounds in identified branches is out of balance in terms 
of number of compounds in branch. This allows to conclude that to now, uracil 
type of compounds have been most studied. NRTIs being nucleoside/nucleotide 
analogues, do not have too much “room” to vary in a structural sense, as they 
should mimic the naturally occurring nucleoside/nucleotide mechanism of action. 
 
 
 
 
 
 
Figure 11. Pyrimidine branch: Color scheme shows the structural hierarchy from parent 
structure (black) to full compound (black, green, blue, red) and intermediate scaffolds. 
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2.4. QSAR-s for HIV-1 NNTRIs and NRTIs 
Data sets assembled from the ChEMBL database for HIV-1 NNRT and NRT 
inhibitors are unique because of at least two main reasons. They are in chemical 
terms very diverse and are characterized by binding affinity equilibrium constants. 
This, in addition to hierarchical classification and analysis of structural landscape, 
provides opportunity to derive QSAR models for both types of inhibitors that 
have not been present before in currently available literature (see Introduction to 
Article II).  
From the hierarchical classification analysis (in Article II, Table 1), one 
could see that NNRTI’s dataset is rather diverse but unbalanced towards 
structural patterns in the oxazepanone, piperazinone, and pyrazine branches. 
This gave a challenge for establishing training and validation sets in the way 
that structural diversity is best covered in the training set. It lead to a chemical 
structure intuitive approach with four rules, giving approximately 80:20 ratio 
between training and validation sets that is optimal for the given number of 
compounds in the dataset. Rules are as follows: (i) each parent structure with 
only one compound remains in the training set; (ii) for the remaining parent 
structures, experimental values are aligned from largest to smallest; (iii) for 
parent compound groups with seven or fewer compounds only one compound 
from the middle of the alignment was selected to the validation set. (iv) for the 
two remaining cases, two compounds from the edges of the alignment were 
selected to the validation set. This approach is essential, because the dataset was 
chemically diverse and numerically small, where a structural diversity should be 
represented first and foremost in the training data set. As a result, 31 
compounds were listed in the training set and 8 in the validation set (in Article 
II, Table 1).  
 
log Ki(NNRTI) = –12.303 (±2.075)Nrel– 1.637 (±0.427) ߳௅௎ெை + 0.628 (0.295) 
ܫܥଶ  + 3.507 (±1.149) 
2R =0.7080, 2cvR =0.6317, 
2
extR =0.7248, 
2
scrR =0.1, s
2=0.2230, ntr=31, nval=8 
(1) 
 
The QSAR model (Equation (1)) for NNRTIs include three molecular descriptors 
[148, 172]: energy of the lowest unoccupied molecular orbital (߳௅௎ெை), relative 
number of nitrogen atoms (Nrel) and average information content (order 2) 
( ܫܥଶ ). The relationship of binding affinity vs. molecular descriptor enables to 
analyze trend in more detailed. The first two descriptors indicate that 
compounds with lower LUMO (Lowest Unoccupied Molecular Orbital) energy 
and smaller content of nitrogen have the higher binding affinity (in Article II, 
Figure 12: c). All compounds in the NNRTI dataset have at least one nitrogen 
present in the molecular ring and the number of nitrogen atoms goes up to eight 
when considering substituents and sidechains. The energy of the lowest 
unoccupied molecular orbital and the relative number of nitrogen atoms, both 
have also substantial impact on binding affinity. The nitrogen atom is involved 
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in electrostatic interactions with hydrophilic amino acids and the LUMO energy 
has impact on hydrophobic interactions. Both explanations are relevant because 
the NNRTI binding pocket contains a hydrophobic sub-pocket with aromatic 
residues Tyr181 (Tyrosine 181), Tyr188 (Tyrosine 188), Phe227 (Phenylalanine 
227) and Trp229 (Tryptophan 229) and hydrophilic amino acid residues such as 
Lys101 (Lysine 101) or Lys103 (Lysine 103) [173]. The third descriptor is 
topological and has a positive contribution, meaning that compounds with more 
diverse structural content and bonding pattern have higher binding affinity. In 
general, the prediction quality of the model shows good stability, particularly 
towards the external validation set (in Article II, Figure 12).  
A similar approach with NNRTIs was used in compiling the training and 
validation sets as for the NRTIs. For NRTIs, the data points were well-
distributed over the scale of experimental values and almost half of the dataset 
are uracil-based compounds (in Article II, Table 2). 26 NRTIs remained in the 
training set and 6 NRTIs were separated to the validation set (in Article II, 
Table 2).  
 
log Ki(NRTI) = –35.133 (±5.479) ܵܫܥଶ  + 0.766 (±0.015) XlogP3 – 13.518 
(4.400) VM/XmaxYmaxZmax + 44.418 (±5.494) 
R2=0.7000, 2cvR =0.5875, 
2
extR =0.7445, 
2
scrR =0.12, s
2=0.3812, ntr=26, 
nval=6 
(2) 
 
The QSAR model for NRTIs (Equation (2), in Article II, Figure 18) also includes 
three molecular descriptors: ܵܫܥଶ 	(average structural information content) [172]; 
XlogP3 (calculated logarithm of octanol-water partition coefficient) and 
VM/XmaxYmaxZmax (molecular volume / XYZ Box) [148]. The first and third 
descriptors have negative correlation with the binding affinity, meaning that 
compounds with less diverse content and less compact compounds have higher 
binding affinity. The second descriptor has a positive correlation, showing that, 
if hydrophobicity of a compound increases, the binding affinity also increases. 
Comparison of the prediction quality of the model indicates stability, for 
external validation set 2extR  being higher and for the cross-validated correlation 
coefficient being smaller in comparison with the R2; both are strongly 
influenced by the size of the datasets and distribution of data points (in Article 
II, Figure 18).  
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3. CONCLUSION 
Current thesis focused on two highly prevalent infections affecting many 
regions in the world: malaria and human immunodeficiency virus 1. Developing 
a new drug from scratch is time consuming and costly. This has been 
conventionally divided into five stages: basic research, lead target and lead 
compound(s) discovery, preclinical development, clinical development and 
filing to drug administration agency. Research within present thesis focuses on 
experimental and computational areas in early drug discovery processes. 
In the case of HIV-1, the focus was two-fold. First, based on the earlier 
multi-objective in silico screening, novel s-triazine derivatives (8, 17, 18, 18a, 
18b, 19) were designed, discovered, and synthesized, where findings where 
supported by the modelling tasks and biological evaluation. The most potent 
compound 18b proved to be non-toxic and effective in both cell-based and 
enzyme experiments. The small molecular size, potent ligand efficiencies, and 
measured low toxicities permit further exploration of its derivatives. Second, 
these identified s-triazines motivated to analyze the publicly available HIV-1 
RT inhibitors to find out how the discovered compounds position on the 
landscape of NNRTI inhibitors. For this, local focused datasets were created for 
HIV-1 NNRTIs and NRTIs based on retrieved data from in-house and from 
online ChEMBL database. Extracted data was carefully filtered, curated and 
grouped into 32 NRTIs and 39 NNRTIs.  
The generated HIV-1 RT inhibitor datasets were analyzed using a 
hierarchical classification method to discover the structural hierarchy in existing 
HIV-1 NNRTIs and NRTIs. The NNRTIs and NRTIs were dealt as separate 
subsets. Analysis of the HIV-1 NNRTIs resulted in ten different common 
structural ‘parent types’ and the HIV-1 NRTIs were divided into four different 
‘parent types’. Previously discovered s-triazines formed a separate structural 
‘parent type’ group. Each ‘parent type’ group was analyzed and examined by 
means of binding affinity equilibrium constants (Ki) assigned to each individual 
structure. The scaffolds affecting the potency and stability were highlighted. 
The unique datasets allowed the development of descriptive and predictive 
QSAR models for both HIV-1 NNRTIs and NRTIs groups. The obtained QSAR 
models include three different, mechanistically relevant molecular descriptors. 
Analysis of the trends in descriptors revealed important structural parameters 
and how they influence the binding affinity of molecules. Such QSAR models 
for data series with binding affinity equilibrium constants have not been 
published up to now and can aid in predicting new compounds. 
To find new promising antimalarial compounds, the experimental anti-
Plasmodium data from in-house data source and from online ChEMBL database 
were used. Data from both sources was extensively curated, systematically 
analyzing experimental protocols and three common compounds. Also, 
chemical structures were carefully curated, fused and filtered, and finally, a 
procedure was developed to group different data series into 30 data sets for the 
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modelling. Out of 30 data series, 17 showed promising models when developed 
with the support vector machine classification consensus approach. Statistical 
significance of these 17 models allowed consensus predictions for virtual 
screening of the series of 72 curcuminoids and 2,6-DATHTPs synthesized in-
house. The top ranking positive predictions (27) together with a few predicted 
as inactive (4) were then submitted to experimental in vitro antimalarial testing. 
A large majority of the predicted compounds (17) showed antimalarial activity, 
but not those predicted as inactive, thus also experimentally validating the in 
silico screening approach.  
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4. SUMMARY IN ESTONIAN 
Disain ja modelleerimine HIV-1 pöördtranskriptaasi ja  
Malaaria ravimite väljatöötamise varajases faasis 
Käesolev uurimus keskendub kahele ohtlikule nakkushaigusele: malaaria ja ini-
mese immuunpuuduikkuse viiruse tüübile 1 (HIV-1). Uue ravimi väljatöötamine 
algusest lõpuni on pikk, keeruline ning kulukas protsess, mida võib tinglikult 
jagada viieks etapiks: baasuuringud; sihtmärgi ja lähteühendi(te) valimine; 
eelkliinilised uuringud; kliinilised uuringud; vajalike dokumentide esitamine 
ravimiametisse. Käesolev töö hõlmab endas kahe esimest ravimiarenduse etappi, 
nn. ravimite väljatöötamise varajases faasi, jooksul tehtavaid tegevusi.  
HIV-1 uurimisel oli kaks põhisuunda. Esmalt teostati uudsete s-triasiini 
derivaatide (8, 17, 18a, 18b, 19) disainimine, avastamine, ja süntees, tuginedes 
eelnevalt tehtud virtuaalsõelumise tulemustele. Läbiviidud raku- ning ensüüm-
katsete tulemuste põhjal osutus ühend 18b saadud ainetest kõige tõhusamaks 
HIV-1 NNRT inhibiitoriks. Ühendi 18b väike molaarmass, tugev ligandi efek-
tiivsus ning mõõdetud madal toksilisus soodustavad antud ühendi edasist modi-
fitseerimist. Teiseks suunaks oli HIV-1 inhibiitorite laiem uurimine, et kindlaks 
teha kas ühendid 18b ja 18a moodustavad HIV-1 RT struktuuriruumis unikaalse 
ühendite grupi. Selleks kasutati olemasolevaid avalikult kättesaadavaid HIV-1 
inhibiitorite andmeid. Esmalt eraldati ChEMBLI andmebaasist HIV-1 RT 
inhibiitorite andmed, kuhu lisati ka kohalikud uudsed s-triasiini derivaadid, et 
võrrelda neid teiste olemasolevate HIV-1 inhibiitoritega. Saadud andmeseeriate 
hoolika kureerimise ja filtreerimise tulemusena jagunesid ühendid kahe gruppi: 
32 NRT ja 39 NNRT inhibiitorit. Andmeseeriates olevate struktuuride vahelisi 
seoseid analüüsiti kasutades hierarhilise klassifitseerimise meetodit, mis jaotas 
struktuurid korrapäraselt gruppidesse. Analüüsi tulemusena saadi, et NNRTI 
andmeseeria jaguneb kümneks erinevaks ‘vanema tüübi’ grupiks millel on 
iseloomulik baasstruktuur millest järgnevad keemilised ühendid tulenevad ning 
NRTI sisaldab nelja erinevat ‘vanema tüübi’ gruppi. Eelnevalt avastatud s-tria-
siinid moodustasid eraldi seisva ‘vanema tüübi’ grupi. Leitud ‘vanema tüübi’ 
gruppe uuriti ning analüüsiti, lisades juurde ka vastavad mõõdetud seondumise 
afiinsuse tasakaalukonstandid (Ki) ning toodi välja struktuurid, mis omavad 
olulist rolli afiinsuse ning stabiilsuse seisukohast. Unikaalsed HIV-1 NNRTI ja 
NRTI andmeseeriad omakorda võimaldasid arendada kirjeldavaid ja ennusta-
vaid QSAR mudeleid. Loodud QSAR mudelid sisaldasid kolme erinevat 
mehhanistlikult olulist deskriptorit. Leitud mudelite ning nendes sisalduvate 
deskriptorite analüüs tõi esile olulised struktuuri parameetrid ning nende mõju 
seondumisafiinsusele uuritavates ühendites. 
Uudsete anti-malaaria ravimikanditaatide leidmiseks koostati fokusseeritud 
andmebaas eksperimentaalsete anti-Plasmodium andmetega. Andebaas sisaldas 
nii asutusesisesed, kui ka ChEMBLI veebiandmebaasis olevaid andmeid. Saadud 
andmete põhjaliku ulatusliku kureerimise, filtreerimise ning andmeseeriate 
ühendamise tulemusena saadi 30 modelleeritavat andmeseeriat, mis sisaldasid 
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igaüks viiskümmend ja enam keemilist ühendit. Nendel andmeseeriatele tuletati 
klassifitseerimise nn. üksmeele prognoosmudelid kasutades tugivektor masinate 
algoritmi. Prognoosmudelite ennustusvõimekuse analüüs näitas, et 17 mudelit, 
mille ennustusvõime on rohkem kui 70% ja rohkem kui 50% aktiivsete ühendite 
poole, on kasutatavad juba sünteesitud ühendite järjestamiseks enne kontroll-
eksperimendi teostamist. Prognoosivõimeliste mudelitega teostati üksmeele 
ennustusi asutusesiseselt olemasolevatele curcuminoidide seerjale (DAA) ning 
nende analoogidele (2,6-DATHTP). Ennustustäpsuse järgi järjestatud ühenditest 
valiti välja kõrgema järjestusega aktiivsed ja ka mitteaktiivsed ühendid millele 
teostati eksperimentaalne valideerimine in vitro katsetega. In vitro kastete 
tulemused andsid 17 potentsiaalset malaaria vastast eelravimit. 
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APPENDIX 1 
Property table for in-house and ChEMBL data 
Column label Information type 
LabID Origin of the compound: 
in the case of in-house data it was identified by person who 
synthesized the compound 
in case of ChEMBL data, the ChEMBL ID without letters 
”CHEMBL” was assigned  
Value – log(IC50[M]) Measured numerical value 
STD DEV Standard deviation value 
relationship Relationship of the value, if it is bigger/smaller/equal to 
given value (>; <; =) 
Protocol ID Protocol used to measure the experimental value  
Ref ID The source ID, from where the value was taken 
 
 
Protocol table for in-house and ChEMBL data
Column label Information type
Protocol ID Protocol used to measure the given/available value  
Protocol name Type of measurement  
Property name Type of property measured  
Target name The target mechanism  
Target organism Parasite strain used  
Ref ligand Compound used as reference  
Units  The unit of measured value  
Solvent Solvent used 
Drug exposure time How long was the drug exposure time  
Hematocritage %  Amount of hematocritage used  
Parasitema %  Amount of parasitema used  
Parasitic stage  Parasitic stage used: synchronized or unsynchronized  
Assay principle  Assay used  
Comments For any additional comments 
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SMILES and LabID table for in-house and ChEMBL data 
Column label Information type 
Structure Compound structure  
Mol weight Molecular weight of the compound  
Formula Compound formula  
LabID  Origin of the compound:  
in the case of in-house data it was identified by person who 
synthesized the compound  
incase of ChEMBL data, the ChEMBL ID without letters 
”CHEMBL” was assigned  
 
 
Reference table for in-house and ChEMBL data
Column label Information type
Ref ID The source ID, from where the value was taken  
Protocol ID Protocol used to measure the given/available value 
Journal title in which journal it was published  
Doc source description what type of source the data was taken from  
Pubmed ID Pubmed ID if available  
DOI  Digital Object Identifier if available 
Year Year of data publication 
Volume Volume of source article 
Article title Title of source article 
Abstract Abstract of source article 
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